Boillat Olivier, Spechbach Hervé, Chalandon Yves, Eperon Gilles
Service de Médecine Interne et Générale, Département de Médecine interne, de Réhabilitation et de Gériatrie, HUG, Geneva, Switzerland.
Service d'Hématologie, Département des Spécialités de Médecine, HUG and Faculty of Medicine, University of Geneva, Switzerland.
Swiss Med Wkly. 2015 Nov 2;145:w14181. doi: 10.4414/smw.2015.14181. eCollection 2015.
As a result of a huge effort of the international community, the burden of malaria dropped impressively during the last decade. One of the reasons is probably the availability of effective and safe treatments such as artemisinin derivatives. However, along with the greater use of intravenous artesunate recently in severe malaria, as recommended by the World Health Organization, a new adverse event has been described: post-artesunate delayed haemolysis (PADH). It appears after the end of the treatment in a phase of clinical improvement. Even though several causes may act as co-factors, the mechanism of pitting of the infected erythrocytes is most probably the main explanation. After the description of four PADH cases, we hereby present a short review of the current knowledge on this problem.
由于国际社会的巨大努力,疟疾负担在过去十年中显著下降。原因之一可能是有青蒿素衍生物等有效且安全的治疗方法。然而,随着世界卫生组织推荐的静脉注射青蒿琥酯最近在重症疟疾中使用得越来越多,一种新的不良事件被描述出来:青蒿琥酯治疗后延迟性溶血(PADH)。它出现在治疗结束后的临床改善阶段。尽管有多种因素可能起辅助作用,但受感染红细胞的点彩现象机制很可能是主要解释。在描述了4例PADH病例后,我们在此对关于这个问题的现有知识进行简要综述。